Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Cellectar Biosciences, Inc.
Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option
July 02, 2025
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Tickers
CLRB
Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering
July 01, 2025
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Tickers
CLRB
Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement
June 26, 2025
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Tickers
CLRB
Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)
June 24, 2025
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Tickers
CLRB
Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split
June 18, 2025
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Tickers
CLRB
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma
June 11, 2025
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Tickers
CLRB
Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules
June 05, 2025
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Tickers
CLRB
Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)
June 04, 2025
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Tickers
CLRB
Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update
May 13, 2025
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Tickers
CLRB
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025
May 07, 2025
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Tickers
CLRB
Cellectar Announces Plan to Explore Strategic Alternatives
April 30, 2025
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Tickers
CLRB
Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update
March 13, 2025
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Tickers
CLRB
Cellectar Biosciences to Present at the 37th Annual Roth Conference
March 11, 2025
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Tickers
CLRB
Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025
March 05, 2025
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Tickers
CLRB
Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 05, 2025
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Tickers
CLRB
Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference
January 12, 2025
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Tickers
CLRB
Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring
December 10, 2024
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Tickers
CLRB
Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update
November 18, 2024
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Tickers
CLRB
Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225
November 14, 2024
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Tickers
CLRB
Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer
November 12, 2024
From
Cellectar Biosciences, Inc.
Via
GlobeNewswire
Tickers
CLRB
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.